Nitroglycerine sp spray is a kind of medicine administered to patients who have constant chest pain problems. The chest pain problems are associated with angina, which arises from the inability of some blood vessels to efficiently pump blood to the heart. This condition is known as coronary artery disease. This spray is a relaxer to the blood vessels.
It opens them up and back to their standard diameter so that they can function properly and ensure the right amount of oxygen reaches the heart. By doing this, there will be minimal chest pain to the sufferers of the angina condition (Hoffmann, & May, 2018) .
Delegate your assignment to our experts and they will do the rest.
Indications include heart-related complications like hypertension. Other indications are a pain in the chest, discomfort resulting from angina pectoris and signs of acute myocardial infarctions. When the condition goes to severe levels, it is termed as angina pectoris.
At this level, oral preparations and patches on the skin are available. Despite this, there should be a daily observation of a nitrate-free interval. The reduction of seizures related to this condition is only visible for angina induced by effort. It is still unclear if the medication affects the life expectancy of patients with coronary heart conditions.
The most common administration procedure for nitroglycerine is a tablet placed under the tongue. This method ensures that most of the drug is absorbed into the bloodstream, unlike the normal oral administration of similar medication. Patients are always instructed to stay calm and patient for the drug to dissolve in their sublingual glands
completely (Sekura, & Moore, 2015) . Under emergency conditions like the ICU, it is administered as a 5% dextrose in saline when the sublingual dosage does not prove effective. Also, it can be applied directly to the skin as a 2% ointment so that it can absorb into the patient's blood (Manly, et al., 2016). The application method should be taken with many precautions to avoid undesired irritations.
References
Sekura, R. D., & Moore, R. M. (2015). U.S. Patent No. 9,095,563 . Washington, DC: U.S. Patent and Trademark Office.
Hoffmann, J., & May, A. (2018). Diagnosis, pathophysiology, and management of cluster headache. The Lancet Neurology , 17 (1), 75-83.
Elsohly, M. A., Gul, W., Ashfaq, M. K., & Manly, S. P. (2016). U.S. Patent No. 9,408,822 . Washington, DC: U.S. Patent and Trademark Office.
